🇺🇸 FDA
Patent

US 10364431

Compositions for treating muscular dystrophy

granted A61KA61K31/7125A61P

Quick answer

US patent 10364431 (Compositions for treating muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K31/7125, A61P, A61P1/00, A61P21/00